{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:51:52Z","timestamp":1790247112098,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,2,9]],"date-time":"2014-02-09T00:00:00Z","timestamp":1391904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s11255-014-0663-8","type":"journal-article","created":{"date-parts":[[2014,2,8]],"date-time":"2014-02-08T13:02:51Z","timestamp":1391864571000},"page":"1309-1312","source":"Crossref","is-referenced-by-count":11,"title":["Sunitinib for refractory malignant pheochromocytoma: two case reports"],"prefix":"10.1007","volume":"46","author":[{"given":"Junya","family":"Hata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Haga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souichiro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Akaihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Koguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,9]]},"reference":[{"key":"663_CR1","doi-asserted-by":"crossref","first-page":"872713","DOI":"10.1155\/2012\/872713","volume":"2012","author":"G Parenti","year":"2012","unstructured":"Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giache V, Mannelli M (2012) Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma\/paraganglioma. J Oncol 2012:872713","journal-title":"J Oncol"},{"key":"663_CR2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1677\/ERC-07-0074","volume":"14","author":"A Chrisoulidou","year":"2007","unstructured":"Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14:569\u2013585","journal-title":"Endocr Relat Cancer"},{"key":"663_CR3","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/cncr.23812","volume":"113","author":"H Huang","year":"2008","unstructured":"Huang H, Abraham J, Hung E et al (2008) Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113:2020\u20132028","journal-title":"Cancer"},{"key":"663_CR4","first-page":"260","volume":"33","author":"K Nemoto","year":"2012","unstructured":"Nemoto K, Miura T, Shioji G, Tsuboi N (2012) Sunitinib treatment for refractory malignant pheochromocytoma. Neuro Endocrinol Lett 33:260\u2013264","journal-title":"Neuro Endocrinol Lett"},{"key":"663_CR5","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","volume":"97","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Chougnet CN, Habra MA et al (2012) Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 97:4040\u20134050","journal-title":"J Clin Endocrinol Metab"},{"key":"663_CR6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/jjco\/hyp005","volume":"39","author":"KS Park","year":"2009","unstructured":"Park KS, Lee JL, Ahn H et al (2009) Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol 39:327\u2013331","journal-title":"Jpn J Clin Oncol"},{"key":"663_CR7","first-page":"2231","volume":"125","author":"FK Sun","year":"2012","unstructured":"Sun FK, He HC, Su TW et al (2012) Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma. Chin Med J (Engl) 125:2231\u20132234","journal-title":"Chin Med J (Engl)"},{"key":"663_CR8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/107327481101800205","volume":"18","author":"RH Grogan","year":"2011","unstructured":"Grogan RH, Mitmaker EJ, Duh QY (2011) Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control 18:104\u2013112","journal-title":"Cancer Control"},{"key":"663_CR9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1210\/er.2009-0031","volume":"31","author":"L Ye","year":"2010","unstructured":"Ye L, Santarpia L, Gagel RF (2010) The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev 31:578\u2013599","journal-title":"Endocr Rev"},{"key":"663_CR10","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/cncr.27675","volume":"118","author":"DY Oh","year":"2012","unstructured":"Oh DY, Kim TW, Park YS et al (2012) Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas. Cancer 118:6162\u20136170","journal-title":"Cancer"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-014-0663-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-014-0663-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-014-0663-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T13:18:32Z","timestamp":1565183912000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-014-0663-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,9]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["663"],"URL":"https:\/\/doi.org\/10.1007\/s11255-014-0663-8","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,9]]}}}